Cargando…

Prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy

The RCC‐SELECT study showed the correlation between single nucleotide polymorphisms (SNP) in STAT3 gene and survival in metastatic renal cell carcinoma (mRCC) patients with first‐line interferon‐α (IFN‐α). In that study, even patients with STAT3 SNP linked to shorter overall survival (OS) exhibited...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawano, Yoshiaki, Takahashi, Wataru, Eto, Masatoshi, Kamba, Tomomi, Miyake, Hideaki, Fujisawa, Masato, Kamai, Takao, Uemura, Hirotsugu, Tsukamoto, Taiji, Azuma, Haruhito, Matsubara, Akio, Nishimura, Kazuo, Nakamura, Tsuyoshi, Ogawa, Osamu, Naito, Seiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946720/ https://www.ncbi.nlm.nih.gov/pubmed/27089226 http://dx.doi.org/10.1111/cas.12951

Ejemplares similares

Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan
por: Eto, Masatoshi, et al.
Publicado: (2015)

Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy
por: Shinohara, Nobuo, et al.
Publicado: (2015)

Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
por: Tomita, Yoshihiko, et al.
Publicado: (2022)

Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma
por: Eto, Masatoshi, et al.
Publicado: (2014)

Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
por: Ueda, Takeshi, et al.
Publicado: (2013)

Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1
por: Tsukamoto, Taiji, et al.
Publicado: (2011)

Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community‐based multi‐institutional database across Japan using propensity score matching
por: Onozawa, Mizuki, et al.
Publicado: (2018)

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
por: Akaza, Hideyuki, et al.
Publicado: (2016)

IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation
por: Kato, Taigo, et al.
Publicado: (2022)

Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score
por: Akaza, Hideyuki, et al.
Publicado: (2013)

Topohistology of sympathetic and parasympathetic nerve fibers in branches of the pelvic plexus: an immunohistochemical study using donated elderly cadavers
por: Hinata, Nobuyuki, et al.
Publicado: (2014)

Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
por: Uemura, Motohide, et al.
Publicado: (2020)

Current and Future Gene Therapy for Malignant Gliomas
por: Kanzawa, Takao, et al.
Publicado: (2003)

t(6; 11) renal cell carcinoma. A case report successfully diagnosed by using fluorescence in situ hybridization
por: Nishizawa, Hidekazu, et al.
Publicado: (2021)

Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy
por: Yamamoto, Yutaka, et al.
Publicado: (2016)

Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial
por: Noguchi, Masanori, et al.
Publicado: (2020)

Local advanced adrenocortical cancer with a long‐term recurrence‐free survival treated with complete surgical excision and adjuvant therapy with a very low‐dose mitotane
por: Tokura, Yuumi, et al.
Publicado: (2020)

SCRUM‐Japan GI‐SCREEN and MONSTAR‐SCREEN: Path to the realization of biomarker‐guided precision oncology in advanced solid tumors
por: Nakamura, Yoshiaki, et al.
Publicado: (2021)

PD-L1 expression in papillary renal cell carcinoma
por: Motoshima, Takanobu, et al.
Publicado: (2017)

Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study
por: Ozono, Seiichiro, et al.
Publicado: (2018)

A case of congenital single testis with testicular cancer patient and azoospermia who was able to collect spermatozoa with ipsilateral Onco‐TESE
por: Hayashi, Kazumasa, et al.
Publicado: (2020)

Significance of Neoadjuvant Hormonal Therapy in Radical Retropubic Prostatectomy: A Retrospective Single-Surgeon Study
por: Yamamichi, Fukashi, et al.
Publicado: (2013)

Proposal of “cyclic therapy”, a novel treatment strategy with targeted agents for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2013)

Efficacy of avelumab plus axitinib for advanced renal cell carcinoma as late-line therapy: A case report
por: Uekawa, Ayano, et al.
Publicado: (2022)

Severe bleeding tendency caused by a rare complication of excessive fibrinolysis with disseminated intravascular coagulation in a 51-year-old Japanese man with prostate cancer: a case report
por: Wada, Yoshihiro, et al.
Publicado: (2012)

Efficacy and Safety of Direct Hemoperfusion Using Polymyxin B-Immobilized Polystyrene Column for Patients With COVID-19: Protocol for an Exploratory Study
por: Terada-Hirashima, Junko, et al.
Publicado: (2022)

Rapid Increase of the Serum PSA Level in Response to High-Intensity Focused Ultrasound Therapy may be a Potential Indicator of Biochemical Recurrence of Low- and Intermediate-Risk Prostate Cancer
por: Inamoto, Teruo, et al.
Publicado: (2011)

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy
por: Kikawa, Yuichiro, et al.
Publicado: (2022)

Aging-associated and CD4 T-cell–dependent ectopic CXCL13 activation predisposes to anti–PD-1 therapy-induced adverse events
por: Tsukamoto, Hirotake, et al.
Publicado: (2022)

Site-specific Risk Stratification Models for Postoperative Recurrence and Survival Prediction in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy: Better Stratification for Adjuvant Therapy
por: Miyake, Makito, et al.
Publicado: (2022)

Efficacy of Over-The-Scope Clip Method as a Novel Hemostatic Therapy for Colonic Diverticular Bleeding
por: Kawano, Koichiro, et al.
Publicado: (2021)

Personalized Cancer Therapy for Urological Cancers: From Bench to Bedside and Back
por: Uemura, Hirotsugu, et al.
Publicado: (2012)

Down-Regulation of mir-424 Contributes to the Abnormal Angiogenesis via MEK1 and Cyclin E1 in Senile Hemangioma: Its Implications to Therapy
por: Nakashima, Taiji, et al.
Publicado: (2010)

Mechanisms of adverse effects of anti-VEGF therapy for cancer
por: Kamba, T, et al.
Publicado: (2007)

Salvage Reconstructive Surgery During Nivolumab Therapy for a Patient With Hypopharyngeal Cancer
por: Tsushima, Nayuta, et al.
Publicado: (2020)

A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel
por: Noguchi, Masanori, et al.
Publicado: (2021)

Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma
por: Nakagawa, Takashi, et al.
Publicado: (2022)

Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials
por: Eto, Kazuhiro, et al.
Publicado: (2015)

GLI2 expression levels in radical nephrectomy specimens as a predictor of disease progression in patients with metastatic clear cell renal cell carcinoma following treatment with sunitinib
por: Furukawa, Junya, et al.
Publicado: (2016)

Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised study
por: Yokoyama, Osamu, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_u5v40acecg7s24ejkl2tn1d47p